ClinicalTrials.gg
RecruitingNCT06731673Updated Aug 21, 2025

Heat Shock Protein 47 in Thrombosis

An observational study in Venous Thromboembolism (VTE), Acute Myocardial Infarction With ST Segment Elevation and Stroke (in Patients With Atrial Fibrillation), sponsored by University of Aarhus. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by University of Aarhus · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
340
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Venous Thromboembolism with a site in Denmark — 6 open to participants now, 7 under way, 1 of them phase 3. Venous Thromboembolism · Denmark.

Planned enrollment
8th of 13
340 · median 600
Started
2024
the only one that year
Observational
13 of 42
4 open now
Registered
40th of 42
by date
Lead sponsor
3 of 42
University of Aarhus

Among the 42 studies in Venous Thromboembolism with a site in Denmark, this one is the 8th largest by planned enrollment of the 13 observational ones that give a count, is the only one that started in 2024, is one of 13 observational ones, and was the 40th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

6 of the 42 studies in Venous Thromboembolism with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Venous Thromboembolism with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are:

  1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers.
  2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up.
  3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event.

Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.

03

Conditions studied

  • Venous Thromboembolism (VTE)
  • Acute Myocardial Infarction With ST Segment Elevation
  • Stroke (in Patients With Atrial Fibrillation)

Keywords

  • HSP47
  • Heat Shock Protein 47
  • Biomarker
  • Novel biomarker
  • Trombosis
  • VTE
  • AMI
  • Stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited at Aarhus University Hospital at the department of Cardiology (AMI, VTE), Neurology (Stroke) and Radiology (VTE) and at the Blood Bank (Healthy volunteers).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older

VTE group:

  • Deep vein thrombosis confirmed on ultrasonography OR
  • Pulmonary embolism confirmed on computed tomography angiography (CTA)

AMI group:

  • ST-segment elevation on (ECG) AND
  • Culprit lesion(s) on coronary angiography

Stroke group:

  • Stroke confirmed on magnetic resonance imaging AND
  • Atrial fibrillation (Detected on ECG, telemtry or Holter monitoring) AND
  • Stroke localisation classic for AFib: cortical, cerebellar, brainstem or subcortical >1.5 cm in diameter

Healthy group:

- Healthy

Exclusion criteria

Exclusion Criteria:

  • \<18 years of age
  • no
  • Known haematological disorders
  • Active haematological
  • Severe renal insufficiency defined as \<15 or dialysis

VTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT

AMI

  • Coronary dissection
  • Takotsubo cardiomyopathy

Stroke

- Stroke from other causes, e.g. findings pointing towards large vessel disease

Healthy

  • Known acute or chronic disease
  • Prior VTE, AMI, stroke or other thromboembolic event
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
340 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Venous thromboembolism

    Patients with acute deep vein thrombosis diagnosed on UL or pulmonary embolism diagnosed on CTA. \>18 years of age. 120 patients in total.

  • Acute myocardial infarction

    With ST segment elevation on ECG and confirmed culprit lesion on coronary angiography. \>18 years of age. 50 patients in total.

  • Stroke

    Stroke confirmed on MRI and diagnosis of atrial fibrillation. \>18 years of age. 50 patients in total.

  • Healthy participants

    No known or prior diseases, no medication. \>18 years of age. 120 in total.

06

What researchers measure

Primary outcomes

  1. Platelet levels of heat shock protein 47 (HSP47) in patients with thrombosis compared to healthy controls

    The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry.

    Time frame: From enrollment to end of follow-up at 12 months after enrollment. At 3 time points.

Secondary outcomes

  1. Changes in platelet levels of HSP47 over time in patients with thrombosis

    The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry.

    Time frame: From enrollment to 12 months of follow-up. Measured at 3 time points.

  2. Platelet levels of HSP47 in association to platelet function

    The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Platelet function will be assessed by platelet aggregation and activation using impedance aggregometry and flow cytometry.

    Time frame: From enrollment to 12 months of follow-up. Measured at 3 time points.

  3. Platelet levels of HSP47 in association to fibrinolytic capacity

    The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Fibrinolytic capacity will be assessed by ROTEM (R) tPA methods established in our lab, and by plasma fibrinolysis analyses.

    Time frame: From enrollment to 12 months of follow-up. Measured at 3 time points.

07

Study locations

2 of 2 sites recruiting
  • Aarhus University Hospital
    Aarhus, Central Region 8200, Denmark
    Recruiting
    • Kathrine A Friis, PhD-student · Contactkathrinefriis@live.dk · +45 20 86 75 94
    • Erik L Grove, Assoc. Prof., MD · Principal investigator
    • Kathrine A Friis, MD, PhD-fellow · Sub investigator
  • Deutsches Herzzentrum de Charité
    Berlin, State of Berlin 12203, Germany
    Recruiting
08

References and documents

Publications

  • Thienel M, Muller-Reif JB, Zhang Z, Ehreiser V, Huth J, Shchurovska K, Kilani B, Schweizer L, Geyer PE, Zwiebel M, Novotny J, Lusebrink E, Little G, Orban M, Nicolai L, El Nemr S, Titova A, Spannagl M, Kindberg J, Evans AL, Mach O, Vogel M, Tiedt S, Ormanns S, Kessler B, Dueck A, Friebe A, Jorgensen PG, Majzoub-Altweck M, Blutke A, Polzin A, Stark K, Kaab S, Maier D, Gibbins JM, Limper U, Frobert O, Mann M, Massberg S, Petzold T. Immobility-associated thromboprotection is conserved across mammalian species from bear to human. Science. 2023 Apr 14;380(6641):178-187. doi: 10.1126/science.abo5044. Epub 2023 Apr 13. PubMed 37053338 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Aug 2027, 32 months after the start.

Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 32 months is below that.

Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 12, 2024
StartActual
Dec 9, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06731673
Collaborators
Aarhus University Hospital, Max Planck Institute of Biochemistry, Deutsches Herzzentrum der Charité, Berlin
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Dec 9, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Aug 21, 2025

Study contacts

Kathrine A Friis, MD, PhD-fellow
Contact
katfrs@rm.dk
+45 20 65 27 32

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion